Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Am Coll Surg. 2014 Feb;218(2):163-9. doi: 10.1016/j.jamcollsurg.2013.10.025. Epub 2013 Nov 12.

Assessment of tumor growth in pancreatic neuroendocrine tumors in von Hippel Lindau syndrome.

Author information

  • 1Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • 2Diagnostic Radiology Department, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • 3Biostatistics and Data Management Section, Office of the Clinical Director, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • 4Department of Surgery, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY.
  • 5Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • 6Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: kebebewe@mail.nih.gov.

Abstract

BACKGROUND:

The incidence of pancreatic neuroendocrine tumors (PNETs) is increasing, but only a subset of these heterogeneous tumors will progress to malignant disease, which is associated with a poor prognosis. Currently, there are limited data on the natural history of these tumors and it is difficult to determine which patients require surgical intervention because the risk of metastatic disease cannot be accurately determined.

STUDY DESIGN:

We conducted a prospective study of 87 patients with von Hippel Lindau syndrome-associated solid pancreatic lesions to determine the natural history of these tumors with biochemical testing, follow-up anatomic and functional imaging, and advanced imaging analysis, with a median follow-up of 4 years.

RESULTS:

Approximately 20% of consecutive tumor measurements during follow-up were decreased in size and 20% showed no change. This included 2 of 4 surgically proven malignant tumors, which had a net decrease in tumor size over time. Tumor volume, as derived from greatest diameter and volumetric measurements, showed good correlation to pathology tumor measurement of surgically resected tumors (Spearman rank correlation ρ = 0.72, p = 0.0011, and ρ = 0.83, p < 0.0001, respectively). Tumor density measurement had an inverse relationship with tumor size (Spearman rank correlation -0.22, p = 0.0047). A tumor density cutoff of 200 was 75% specific for malignant tumors.

CONCLUSIONS:

Pancreatic neuroendocrine tumors demonstrate a nonlinear growth pattern, which includes periods of no growth and apparent decrease in size by imaging. These growth patterns are variable and are not associated with tumor grade and malignancy. Tumor density, as measured in this cohort, may offer a specific diagnostic tool for malignant disease.

Published by Elsevier Inc.

KEYWORDS:

CgA; PNET; PPP; VHL; chromogranin A; pancreatic neuroendocrine tumor; pancreatic polypeptide; von Hippel Lindau syndrome

PMID:
24440063
[PubMed - indexed for MEDLINE]
PMCID:
PMC3896892
[Available on 2015/2/1]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk